Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Oryzon Genomics (ORY SM)
Watchlist
54
Analysis
Health Care
•
Spain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Oryzon Genomics
•
22 May 2018 17:27
•
Issuer-paid
Oryzon Genomics - Phase IIa trial in Alzheimer’s disease initiated
According to the latest news from Oryzon, the first Alzheimer’s disease (AD) patients (3/90) were recruited into the Phase IIa ETHERAL clinical...
Edison Investment Research
Follow
58 Views
Share
bullish
•
Oryzon Genomics
•
08 Mar 2018 19:12
•
Issuer-paid
Oryzon Genomics - Multiple data readouts in 2019 within cash reach
Oryzon is ramping up its R&D programme and plans to conduct a total of four mid-stage clinical trials with lead assets ORY-1001 (a specific...
Edison Investment Research
Follow
85 Views
Share
bullish
•
Oryzon Genomics
•
14 Dec 2017 15:28
•
Issuer-paid
Oryzon Genomics - New data support holistic effects of ORY-2001
Recently, Oryzon has published a flurry of fresh preclinical data backing its products ORY-2001 and ORY-3001. Latest data from ORY-2001 expanded...
Edison Investment Research
Follow
42 Views
Share
bullish
•
Oryzon Genomics
•
22 Aug 2017 18:08
•
Issuer-paid
ORY-1001 rights back to Oryzon
Roche’s decision to discontinue the development of ORY-1001 and return the rights to Oryzon was major recent news. Roche cited portfolio...
Edison Investment Research
Follow
77 Views
Share
bullish
•
Oryzon Genomics
•
21 Jul 2017 17:57
•
Issuer-paid
Roche returns rights on ORY-1001
As reported yesterday, Roche has decided to discontinue the development of ORY-1001 (a selective LSD1 inhibitor) and return the rights to Oryzon,...
Edison Investment Research
Follow
40 Views
Share
First
Previous
7
8
9
10
11
Next
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x